SI
SI
discoversearch

Biotech / Medical
Spectral Medical Inc.
An SI Board Since October 2011
Posts SubjectMarks Bans Symbol
290 9 0 EDTXF
Emcee:  Sultan Type:  Unmoderated
Spectral is a Phase III company seeking U.S. FDA approval for its lead theranostics product for the treatment for severe sepsis and septic shock. Toraymyxin is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis. Spectral's EUPHRATES trial is the world's first theranostics trial in the area of sepsis.

Toraymyxin has been approved for therapeutic use in Japan and Europe , and has been used safely and effectively in more than 80,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for Toraymyxin, and in November 2010, signed an exclusive distribution agreement for this product in Canada . More than 250,000 patients are diagnosed with severe sepsis and septic shock in North America each year, representing a greater than $1 billion market opportunity for Spectral. Spectral is listed on the Toronto Stock Exchange under the symbol SDI.

For further information please visit spectraldx.com
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
290dailymail.co.ukvilliago-December 5
289One reason from a knowledgeable, respected source: Message 31127355The Ox-November 28
288dailymail.co.uk How can this not be a $2 to $3 stock?villiago-November 28
287America Has a $27 Billion Sepsis Crisis bloomberg.comSultan2November 27
286Spectral Announces Third Quarter Results finance.yahoo.comSultan-November 14
285 35th International Vicenza Course on AKI & CRRT youtube.comSultan-November 14
284Spectral Provides Update on FDA Meeting Regarding Its PMA Submission for ToraymySultan1October 31
283Critical Care Canada Forum (CCCF) Toronto Plenary Session Presentation: Sultan1October 15
282Sepsis & septic shock market to be worth $5.9 billion by 2026 linkedin.comSultan1October 15
281Spectral Presents Key EUPHRATES Trial Data at the Canadian Critical Care Forum Sultan1October 4
280Spectral Provides Regulatory Update on Its PMA Submission for Toraymyxin™ TORONSultan-September 21
279Nice accumulations going on in the public side as well. Saw a 125,000 share dayvilliago-August 18
278Insiders Transactions canadianinsider.comSultan-August 18
277 August 11, 2017 08:00 ET Spectral Announces Second Quarter Results TORONTvilliago-August 14
276 Investor Update July 31, 2017 spectraldx.comSultan2July 31
275Right.. We should hear about the standalone pump pretty soon.. According to tSultan-July 24
274Very muted reaction but at least we're still in the game.JSB-July 24
273FDA Accepts Spectral's PMA for Toraymyxin(TM) for Review TORONTO, ONTARIO-Sultan1July 24
272Registration for tomorrow's presentation at 11.30 am EDT is open at stream6.Sultan-June 13
271Spectral's Trial Data to Be Presented at 35th Vicenza Course on AKI and CRRTSultan-June 12
270Presentation at AGM spectraldx.comSultan1June 2
269Umm, last fall, see your post #248.CusterInvestor-June 1
268I am not sure what you are referring to.. As far as Spectral goes, this trial isSultan-May 31
267Does anyone know how this submission is any better than the last one which did nCusterInvestor-May 31
266Why time is of the essence in treating sepsis — a growing killer in Canada cbc.Sultan-May 31
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2017 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.